Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
  
Advanced search 
 
Year : 2000  |  Volume : 21  |  Issue : 1  |  Page : 21-27

Ceftazidime and netilimicin versus ceftazidime and amikacin for febrile neutropaenia.


Department of Medical Oncology, Tata Memorial Hospital, Mumbai

Correspondence Address:
DK Hawse
Department of Medical Oncology, Tata Memorial Hospital, Mumbai

Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

A total of 50 patients having high risk febrile neutropaenia were entered in the study, randomly and were assigned to receive either ceftazidime and netilmicin or ceftazidime and amikacin. Seventeen out of 25 (68 per cent) febrile episodes responded to ceftazidime and netilmicin while 12/25 (48 per cent) episodes responded to ceftazidime and amikacin. Total 26/50 (52 per cent) febrile episodes were diagnosed as FUO. Out of them, 15/16 (93.73 per cent) patients responded to ceftazidime and netilmicin and 4/10 (40 per cent) patients responded to ceftazidime and amikacin. The most common organisms grown were Gram-negative bacteria (26/29, 89.65 per cent) like E. coli, Pseudomonas, Klebsiella and Acinetobacter. Gram-positive bacteria were grown in 3/29 (11.35 per cent) episodes only. Though eight out of the 15 (16 per cent) episodes were associated with bacteremia. Of them, 1/13 (33.33 per cent) and 5/5 (100 per cent) episodes responded to ceftazidime and netilmicin and ceftazidime and amikacin, respectively. The median duration of therapy was 6 (4 to 12) days in the ceftazidime and netilmicin group and 8 (4 to 13) days in the ceftazidime and amikacin. A change in the antimicrobial was required in 8/25 (32 per cent) patients in the ceftazidime and netilmicin group, while in the ceftazidime and amikacin group a change in the antibiotics was required in 13/25 (52.5 per cent) cases. We conclude that combination of ceftazidime and netilmicin is found to be equally effective as the combination of ceftazidime and amikacin in febrile neutropaenic patients.


[PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed674    
    Printed48    
    Emailed1    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal